Investigating brain changes in patients with progressive apraxia of speech
Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech
PHASE4 · Mayo Clinic · NCT01818661
This study is trying to see how changes in the brain affect speech difficulties over time in people with progressive apraxia of speech.
Quick facts
| Phase | PHASE4 |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Mayo Clinic (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Rochester, Minnesota) |
| Trial ID | NCT01818661 on ClinicalTrials.gov |
What this trial studies
This study aims to explore the relationship between structural and functional brain changes observed through imaging techniques and the progression of speech and language difficulties in patients diagnosed with neurodegenerative apraxia of speech (AOS). It focuses on understanding how AOS, often associated with non-fluent aphasia, manifests and evolves over time, potentially leading to cognitive impairments. The study will utilize AV-1451 as an intervention to assess these changes in a longitudinal manner, providing insights into the neurological underpinnings of the disorder.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with neurodegenerative apraxia of speech at the Mayo Clinic.
Not a fit: Patients with speech and language deficits due to concurrent illnesses like traumatic brain injury or strokes will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and therapeutic strategies for patients suffering from apraxia of speech and related conditions.
How similar studies have performed: While there is ongoing research in related areas, this specific approach focusing on the longitudinal imaging of AOS is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * We will study subjects that fulfill clinical inclusion criteria for neurodegenerative AOS that have been seen and diagnosed at Mayo Clinic Exclusion Criteria: * Subjects with concurrent illnesses that could account for speech and language deficits, such as traumatic brain injury, strokes or developmental syndromes will be excluded. * Women that are pregnant or post-partum and breast-feeding will be excluded. All women who can become pregnant must have a pregnancy test no more than 48 hours before the PET scan. * Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma or intracranial neoplasm), or if they are medically unstable or are on medications that might affect brain structure or metabolism,(e.g. chemotherapy). * Subjects will also be excluded if they do not have an informant, or do not consent to research.
Where this trial is running
Rochester, Minnesota
- Mayo Clinic — Rochester, Minnesota, United States (RECRUITING)
Study contacts
- Principal investigator: Jennifer Whitwell, PhD — Mayo Clinic
- Study coordinator: Sarah Boland, CCRP
- Email: boland.sarah@mayo.edu
- Phone: 507-284-3863
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: PPA, Non-fluent Aphasia, Apraxia of Speech, Primary Progressive Non-fluent Aphasia, Primary Progressive Aphasia, apraxia of speech, non-fluent aphasia, aphasia